What is Wedbush’s Forecast for VERA FY2029 Earnings?

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Vera Therapeutics in a research note issued on Thursday, February 27th. Wedbush analyst L. Chico anticipates that the company will earn $2.16 per share for the year. Wedbush currently has a “Neutral” rating and a $38.00 price target on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics’ FY2029 earnings at $2.16 EPS.

A number of other brokerages have also recently commented on VERA. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. JPMorgan Chase & Co. lifted their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 target price on the stock. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. Finally, Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $65.11.

Vera Therapeutics Stock Up 1.8 %

Shares of VERA stock opened at $29.93 on Friday. Vera Therapeutics has a 12 month low of $25.99 and a 12 month high of $51.61. The stock has a market cap of $1.90 billion, a P/E ratio of -11.47 and a beta of 1.11. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a 50 day simple moving average of $35.75 and a two-hundred day simple moving average of $40.33.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VERA. Avoro Capital Advisors LLC increased its holdings in Vera Therapeutics by 30.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after purchasing an additional 1,300,410 shares during the period. Vestal Point Capital LP purchased a new stake in Vera Therapeutics during the fourth quarter worth $45,462,000. Lord Abbett & CO. LLC lifted its holdings in Vera Therapeutics by 170.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company’s stock worth $48,788,000 after buying an additional 727,656 shares during the period. Federated Hermes Inc. lifted its holdings in Vera Therapeutics by 162.2% during the fourth quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company’s stock worth $45,926,000 after buying an additional 671,881 shares during the period. Finally, Integral Health Asset Management LLC lifted its holdings in Vera Therapeutics by 130.0% during the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company’s stock worth $48,634,000 after buying an additional 650,000 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the transaction, the chief executive officer now owns 85,942 shares in the company, valued at $3,701,521.94. The trade was a 16.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 52,500 shares of company stock worth $2,305,625 in the last quarter. 21.70% of the stock is owned by company insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.